Grants per year
Personal profile
Research Interests
I joined Northwestern University in August 2017 as a tenured Professor in Urology. I previously served as a Professor of Microbiology and Immunology at the Medical University of South Carolina and the University of Washington. I obtained a PhD from the University of British Columbia in Canada followed by post-doctoral training in Fred Hutchinson Cancer Research Center (FHCRC) and a faculty position at the University of Washington. My research focuses on understanding how cancer cells edit the immune system with the ultimate goal to develop effective immune therapy to control cancers.
Research in my laboratory include these specific aspects: 1) mechanisms of cancer immune evasion; 2) development of novel cancer immunotherapy; 3) Immune therapy-related mucosal toxicity; 4) mechanisms of cancer therapeutic resistance; 4) cancer biomarker discovery. Prostate Cancer is one of my lab's main focus areas. I am also researching the NKG2D axis in tumors which can be applied to a broad spectrum of cancer types and autoimmunity.
Training Experience
| 2002 | Postdoctoral Fellowship, Fred Hutchinson Cancer Research Center |
Education/Academic qualification
PhD, University of British Columbia
… → 2000
MSc, Peking University
… → 1991
Research interests
- Cancer Biology
- Immune Regulation
- Inflammation
- Inflammatory Bowel Disease
- Interdisciplinary Research
- Prostate Cancer
Fingerprint Dive into the research topics where Jennifer Donglan Wu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 8 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
- 6 Active
Enhancing Anti-CTLA4 Immunology Therapy for Prostate Cancer with Cotargeting Soluble NKG2D Ligand
U.S. Army Medical Research and Materiel Command
10/1/18 → 10/31/20
Project: Research project
Tumor immune and glycan biomarkers for progressive prostate cancer
Abdulkadir, S. A., Jovanovic, B. & Wu, J. D.
12/4/17 → 11/30/22
Project: Research project
A novel serum and tissue immunoglycomic biomarker panel to distinguish progressive Prostate Cancer
U.S. Army Medical Research and Materiel Command
9/30/17 → 9/29/20
Project: Research project
Research Output
How else can we approach prostate cancer biomarker discovery?
Drake, R. R., Angel, P. M., Wu, J., Pachynski, R. K. & Ippolito, J. E., Feb 1 2020, In : Expert Review of Molecular Diagnostics. 20, 2, p. 123-125 3 p.Research output: Contribution to journal › Editorial
Open Access
1
Scopus
citations
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
Zhang, J., Larrocha, P. S. L., Zhang, B., Wainwright, D., Dhar, P. & Wu, J. D., Aug 26 2019, In : Journal for immunotherapy of cancer. 7, 1, 223.Research output: Contribution to journal › Article
Open Access
1
Scopus
citations
CD73: An emerging checkpoint for cancer immunotherapy
Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y. & Zhang, B., Jan 1 2019, In : Immunotherapy. 11, 11, p. 983-997 15 p.Research output: Contribution to journal › Review article
4
Scopus
citations
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)
Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C., Lukas, R. V., Binder, D. C. & Wainwright, D. A., Mar 4 2019, In : OncoImmunology. 8, 3, 1548242.Research output: Contribution to journal › Comment/debate
Past, Current, and Future of Immunotherapies for Prostate Cancer
Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. & Wu, J. D., Sep 11 2019, In : Frontiers in Oncology. 9, 884.Research output: Contribution to journal › Review article
Open Access
2
Scopus
citations